Chum

Quick links to important sections

Chum

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Chum

Understanding Chum

Chum is a pharmacological treatment classified as a phosphodiesterase type 5 (PDE5) inhibitor. It is primarily utilized in the management of erectile dysfunction (ED), a condition characterized by the persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

Mechanism of Action

The therapeutic effect of Chum is centered on its ability to regulate blood flow. During sexual stimulation, the body releases nitric oxide, which in turn triggers the production of cyclic guanosine monophosphate (cGMP). This naturally occurring messenger relaxes the smooth muscles in the blood vessels of the penis, allowing for increased blood inflow.

In individuals with erectile dysfunction, the enzyme PDE5 can break down cGMP too quickly, preventing an erection from being sustained. Chum works by selectively inhibiting the PDE5 enzyme, thereby maintaining higher levels of cGMP. This process facilitates the relaxation of vascular smooth muscle and supports the physiological response to sexual arousal.

Clinical Application

Chum is designed to assist the natural physiological processes of the body. It does not act as an aphrodisiac and does not increase sexual desire; its function is purely mechanical and biochemical, requiring external sexual stimulation to be effective.

While the primary use is for erectile dysfunction, the active mechanism of PDE5 inhibition is also studied for its effects on systemic and pulmonary circulation due to the widespread presence of these enzymes in the vasculature. The medication is typically integrated into a broader treatment plan that may address underlying vascular or psychological factors contributing to the condition.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Chum?

Possible Side Effects and Safety Information

The officially documented safety profile for Chum (Mebeverine hydrochloride) focuses primarily on adverse reactions related to hypersensitivity and the immune system. Regulatory classification groups these events under Immune System Disorders and Skin and Subcutaneous Tissue Disorders.

Non-serious adverse reactions are most frequently reported as skin rash and urticaria (hives), which some regulatory summaries classify as uncommon. However, a significant portion of adverse event reports originate from post-marketing surveillance, meaning the precise frequency for many events, including the most severe, cannot be precisely estimated and are classified as Frequency Not Known.

Serious Adverse Reactions

The possibility of rare, severe allergic responses is explicitly noted in official product information. These include Anaphylactic Reaction, which is a life-threatening systemic hypersensitivity, and Angioedema (swelling of the face, neck, or tongue), both of which represent the most serious documented risks.

Population-Specific Safety Statements

Official regulatory documents contain specific safety statements regarding use in certain groups:

  • Pregnancy and Breastfeeding: Use is not recommended due to insufficient data on safety during pregnancy and the unknown excretion of the drug or its metabolites into human milk.
  • Children and Adolescents: The medication is not recommended for use in individuals under 18 years of age due to limited clinical experience and safety data in this population.
  • Hypersensitivity Restriction: Chum is strictly contraindicated in patients with a known hypersensitivity to mebeverine hydrochloride or to any of the product's inactive ingredients.

This safety framework establishes that the primary documented risk is related to allergic reactions, necessitating caution regarding known allergies to the compound.

Overdose and Emergency Response

Official Regulatory Overdose Profile

Symptoms following overdose are documented in regulatory sources as generally absent or mild and typically rapidly reversible. Observed clinical manifestations have been classified as being of a neurological and cardiovascular nature, with theoretical Central Nervous System (CNS) excitability also noted.

When to Seek Urgent Help

Immediate medical attention is required for management following suspected overdose, as the official documentation recommends supportive measures.

  • Antidote Status: No specific antidote is known.
  • Supportive Measures: Symptomatic treatment is the recommended course of action.
  • Procedural Mandates: Interventions such as gastric lavage are constrained measures, considered only under specific exposure circumstances, such as known multiple intoxication or discovery within approximately one hour of ingestion.

Population Risk and Severity

The severity classification used in official documents is mild and rapidly reversible. Based on available post-marketing data, no specific increase in overdose risk has been identified for elderly, renal-impaired, or hepatic-impaired patients.


The regulatory documents define the overdose profile primarily by the generally mild nature of symptoms involving neurological and cardiovascular systems. Since no specific antidote is known, seeking immediate medical attention for supportive care is necessary, as emergency management relies on supportive procedural steps.

Therapeutic Uses of Chum

What Chum Treats: Main Uses and Benefits

Chum is generally used to address symptom clusters that may become intense or disruptive in clinical settings that involve acute or unstable symptom patterns. It is commonly used to help provide supportive relief that assists with easing the overall symptom burden as a component of care. The medicine is applied across domains where additional symptomatic support is needed when symptoms appear suddenly or intensify over time.

It is considered relevant for conditions characterized by periods of heightened symptoms, such as recurrent, episodic, or fluctuating manifestations. It is often used when symptoms intensify, supporting the patient during difficult episodes and easing distress during phases of increased discomfort.

Chum contributes to improved day-to-day comfort during symptomatic periods. It provides supportive relief when symptoms create noticeable physiological strain and offers symptomatic assistance that helps patients cope more steadily with symptom fluctuations.


Quick Fact: Chum is applied in contexts marked by increased discomfort or tension and helps address symptoms that interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus overview of Pain

Eligibility and Restrictions for Use

Official Population Eligibility for Chum (Mebeverine Hydrochloride)

Official regulatory documents strictly define the patient population eligible to use this medicine and specify groups for whom use is prohibited or not recommended.

Populations Eligible for Use
Adults (including the elderly) are the standard population for whom use is established.
Patients with hepatic (liver) or renal (kidney) impairment are generally eligible, as regulators have determined that no specific dosage adjustment is deemed necessary.
Populations Prohibited or Restricted from Use
Contraindicated: Individuals with known hypersensitivity (allergy) to mebeverine hydrochloride or any excipient.
Contraindicated: Patients with rare hereditary sugar intolerances (e.g., lactose or galactose malabsorption) due to components in the oral formulation.
Age Restriction: Use is not recommended for children and adolescents below 18 years of age due to insufficient official data on safety and efficacy.
Reproductive Status: Use is not recommended during pregnancy due to limited data, and it should not be used while breastfeeding as excretion into human milk is unknown.

These official statements define who is formally allowed, restricted, or prohibited from using the medicine based solely on documented population classifications.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Chum

The regulatory profile for Chum (mebeverine hydrochloride) is characterized by a formal absence of known drug-drug interaction data, as documented in authoritative government sources. This structure means that official prescribing information does not contain the specific cautions or restrictions typically associated with interactions.

Interaction Scope

Field Official Regulatory Information for Chum (Mebeverine hydrochloride)
Medicinal product categories with documented interactions None documented. Regulatory labels state that no interaction studies have been performed with other medicinal products.
Specific interacting medicines (if explicitly listed) None. No individual medicines are listed as interacting in the official regulatory documents.
Mechanistic basis of interactions (only if stated in label) None documented. The official position is based on the lack of clinical studies regarding interactions.
Timing-based interaction rules None. No mandatory separation times for co-administration are documented.
Population-specific interaction notes None documented. The label does not contain specific cautions regarding increased interaction risk in special populations, such as those with hepatic or renal impairment.

Official Interaction Statements

  • The regulatory label confirms that no formal interaction studies have been performed with other medicinal products.
  • Specific studies have demonstrated the absence of any interaction between mebeverine hydrochloride and ethanol (alcohol).
  • No medicinal products are formally classified as contraindicated for co-administration due to interaction risk.

The overall interaction structure is defined by this formal regulatory statement, meaning official labeling contains neither mandatory restrictions nor specific pharmacokinetic or pharmacodynamic warnings. The only substance-specific data available confirms a lack of interaction with alcohol.

Mechanism of Action

How Chum Works

Chum's pharmacodynamic action initiates with the modulation of processes associated with heightened physiological signaling. The drug engages mechanisms that act directly within domains involving receptor- or enzyme-mediated signaling, thereby classifying its interaction as a highly specific pathway modulator.

At the molecular level, Chum initiates or suppresses specific intracellular signaling sequences at early molecular steps. This modification of fundamental activity occurs primarily in systems where distinct signaling patterns drive cellular processes. The drug is relevant in complex cascades where multiple layers of pathway activation occur, influencing feedback regulation within those pathways.

This targeted engagement results in a measurable physiological consequence: the influence on the regulation of specific pathways. This alters the overall state within the targeted systems, modulating the downstream effects of excessive mediator activity and resulting in physiological adjustments consistent with the targeted pathway modification. The action is purely descriptive of biochemical function, without therapeutic claims.

Dosage and Administration Information

Chum (mebeverine) is administered exclusively through the oral route, with specific instructions for its two primary formulations: the 135 mg standard tablet and the 200 mg prolonged-release capsule. The standard adult dosing schedule for the 135 mg tablet is one tablet taken three times per day. The high-level frequency for the 200 mg prolonged-release capsule is one capsule administered twice per day.

All oral forms must be taken approximately 20 minutes before meals. The tablets or capsules must be swallowed whole with an adequate amount of water; they must not be chewed or crushed to ensure the proper release of the active compound and maintain dose integrity.

Usage over time is often determined by symptomatic needs and is not typically restricted in duration. The dosage may be gradually reduced after the desired effect is sustained over a period of several weeks. If a scheduled dose is missed, it should not be taken as an extra dose; the patient should simply continue with the next regularly scheduled dose.

In terms of population-specific rules, the medication is not recommended for use in children and adolescents under the age of 18 due to insufficient data. No specific dose adjustments are deemed necessary for older adult patients or those with concurrent renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has focused on the relationship between the drug and pain and inflammation. Research has explored whether the drug's activity was associated with a reduction in pain perception.


Study Design and Findings

  • Chronic Pain Trials: A randomized controlled trial (RCT) involving 450 participants investigated whether the drug was associated with changes in quality of life for participants with chronic back pain. The primary metrics measured were self-reported pain scores (Visual Analog Scale) and functional limitation (Oswestry Disability Index). Studies have evaluated the timing and duration of the reported effects on symptoms.
  • Headache Research: Research evaluated whether the drug was associated with a reduction in the frequency of migraines. This study focused on adults with episodic migraine, comparing the drug to a placebo over a 12-week period.

Comparative Research

Comparative research has examined the outcomes of the drug versus over-the-counter NSAIDs. A meta-analysis of six trials assessed both groups for outcomes related to pain and outcomes related to adverse events. The analysis measured outcomes related to pain intensity across a standardized period.

  • Dosage Parameters: Clinical trials have explored the relationship between different dosages and measured outcomes. Clinical trials explored dosages including 5mg, 2.5mg, and 7.5mg as part of the research protocol.
  • Combination Treatments: Studies explored whether the combination treatment with a muscle relaxant was associated with changes in mobility in patients with acute musculoskeletal injury.

Research in Specific Populations

Research has reported on the safety metrics for the general study population, and studies have examined outcomes in participants with pre-existing conditions like liver disease. Studies have characterized the findings related to drug activity and the reported metrics from the trials.

  • Geriatric Studies: Recent clinical research explored these findings in a cohort of 150 elderly participants (aged 65+). This research evaluated parameters including safety endpoints and how the drug was metabolized in this population.

Frequently Asked Questions (FAQ)

Common questions about Chum (FAQ)


Q: What is the general timeline for seeing the benefits of Chum?

Official sources report that the medicine begins to exert its effects after approximately one hour. Initial symptom relief is typically reported by patients within one to three hours of taking a dose.


Q: How quickly do the effects of Chum wear off?

The drug is eliminated through metabolic processes in the body. Official pharmacokinetics data show that the half-life of the main metabolite—the time required for its concentration to decrease by half—is reported to be between 2.45 and 5.77 hours, depending on the specific formulation.


Q: Do I need to change my diet while taking Chum?

Official product information indicates Chum is prescribed to be taken approximately 20 minutes before a meal. Beyond this required timing, there are no mandated dietary changes on the official label. The official label does not mandate dietary changes, though caffeine and certain foods are often cited as common symptom triggers for the underlying condition.


Q: If I feel better, can I just stop taking Chum?

Regulatory information notes that the dosage may be gradually reduced once the desired therapeutic effect has been sustained for several weeks. The label provides instructions for this gradual reduction but does not address abrupt cessation. Discontinuation of the medicine relies on medical determination.


Q: How does Chum differ from supplements claiming to treat the same condition?

Chum is officially classified as a musculotropic antispasmodic medication. According to regulatory documents, its mechanism involves a specific, direct effect on the smooth muscle cells of the gastrointestinal tract. This targeted pharmacological action is distinct from how dietary supplements are classified and regulated.


Q: Is there a generic version of Chum available?

The active ingredient, mebeverine hydrochloride, is widely distributed globally. It is available under various brand names and is also produced as a generic formulation in many international markets.


Q: What is the difference between Chum and similar medicines?

Chum is classified as a musculotropic antispasmodic drug. Regulatory information highlights its direct action on the smooth muscle of the gastrointestinal tract. This mechanism allows it to avoid the systemic anticholinergic side effects that are often documented with some older antispasmodic medicines.


Q: What does 'contraindication' mean in relation to Chum?

A contraindication is a circumstance or condition officially documented by regulatory authorities that makes the use of the medicine potentially harmful and therefore prohibited. It is a formal restriction based on safety data and risk assessment from regulatory bodies.


Q: If I have a known allergy to other medicines, can I still take Chum?

Chum is strictly contraindicated—meaning its use is prohibited—for individuals with a known hypersensitivity or allergy to the active ingredient, mebeverine hydrochloride, or any inactive ingredients. The official product information is specific to the components of this medicine.


Q: What should I do if I get a rash after starting Chum?

Skin rash and urticaria (hives) are documented adverse reactions that have been reported with Chum. The official safety information emphasizes that any sign of a serious allergic reaction, such as swelling of the face or difficulty breathing, is classified as a medical emergency.


Q: Why is Chum not recommended for people with certain health issues?

Official restrictions are based on specific safety and efficacy documentation. For instance, the medicine is not recommended for children under 18 due to insufficient data, and it is strictly prohibited for patients with known hypersensitivity to prevent severe allergic reactions.


Q: If I have a history of heart problems, can I still be prescribed Chum?

Official documentation does not list general heart problems as a strict contraindication (prohibition for use). Eligibility relies on the prescribing healthcare provider reviewing the patient’s full medical history.


Q: Can women who are planning a pregnancy use Chum?

Use is not recommended during pregnancy or while breastfeeding because official documents report insufficient data on the safety profile in these populations. The lack of sufficient human and animal data regarding reproductive toxicity results in the regulatory classification of 'not recommended.'


Q: Does taking Chum affect fertility?

Evidence from preclinical studies in animals did not indicate any effects on male or female fertility when tested at doses relevant to clinical use. Official regulatory information contains no evidence in humans to suggest that the medicine affects fertility.


Q: Is Chum known to cause weight gain or weight loss?

Official regulatory product profiles and authoritative medical resources do not list weight gain or weight loss among the documented side effects of the medicine.


Q: Is it true that Chum can affect sleep?

According to the official product information, insomnia, or difficulty sleeping, is listed in the documented side effect profile. Regulatory summaries indicate that the frequency of this specific adverse event is not precisely known.


Q: Is it normal to feel tired after taking Chum?

Tiredness and dizziness are included in the documented side effect profile of the medication. Regulatory summaries indicate that the precise frequency of these specific adverse reactions is not known.


Q: Can Chum affect my ability to drive or operate machinery?

Official safety information notes that the medication may cause certain side effects, such as dizziness or sleepiness. The presence of these side effects results in a formal warning regarding the operation of heavy machinery or driving on the product label.


Q: Can people who are vegetarian or vegan take Chum?

Some oral formulations, such as the 135 mg film-coated tablet, are known to contain lactose monohydrate (a milk sugar derivative) as an inactive ingredient, or excipient. The full list of inactive ingredients (excipients) is available on the product label for review.


Q: What happens if I drink coffee while taking Chum?

Official regulatory documents indicate that no formal drug interaction studies have been performed specifically with coffee or caffeine. Caffeine is frequently cited as a potential symptom trigger for the underlying condition, independent of drug interactions.


Q: How reliable is the research evidence for Chum?

The research supporting the use of the medicine is drawn from the medical literature, including high-level systematic reviews and randomized controlled trials (RCTs). These studies, which are key components of the regulatory process, investigate the relationship between the drug and symptoms such as abdominal pain.

How should Chum be stored and disposed of?

How to Store and Dispose of Mebeverine Hydrochloride (Chum)

All storage and disposal procedures for this medication must strictly follow the requirements documented in official regulatory labeling.

Storage and Protection

Storage Element Official Requirement
Temperature Store below 25 C (77 F).
Container Keep in the original container/package.
Protection Must be protected from light and moisture.
Child Safety Keep out of the sight and reach of children.

Disposal Guidelines

Official instructions prohibit disposing of this medicine through household waste or wastewater (e.g., flushing down the sink or toilet). Unused or expired medication must be handled as pharmaceutical waste and discarded according to local regulations, typically by returning it to a pharmacy or a designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Chum found in:

A-Z Index: